179 related articles for article (PubMed ID: 36513316)
1. Novel mucoadhesive celecoxib-loaded cubosomal sponges: Anticancer potential and regulation of myeloid-derived suppressor cells in oral squamous cell carcinoma.
Mabrouk AA; El-Mezayen NS; Tadros MI; El-Gazayerly ON; El-Refaie WM
Eur J Pharm Biopharm; 2023 Jan; 182():62-80. PubMed ID: 36513316
[TBL] [Abstract][Full Text] [Related]
2. Diet-induced obesity accelerates oral carcinogenesis by recruitment and functional enhancement of myeloid-derived suppressor cells.
Peng J; Hu Q; Chen X; Wang C; Zhang J; Ren X; Wang Y; Tao X; Li H; Song M; Cheng B; Wu T; Xia J
Cell Death Dis; 2021 Oct; 12(10):946. PubMed ID: 34650054
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cells and plasmacytoid dendritic cells are associated with oncogenesis of oral squamous cell carcinoma.
Kouketsu A; Haruka S; Kuroda K; Hitoshi M; Kensuke Y; Tsuyoshi S; Takahashi T; Hiroyuki K
J Oral Pathol Med; 2023 Jan; 52(1):9-19. PubMed ID: 36380437
[TBL] [Abstract][Full Text] [Related]
4. Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma.
Pang X; Fan HY; Tang YL; Wang SS; Cao MX; Wang HF; Dai LL; Wang K; Yu XH; Wu JB; Tang YJ; Liang XH
PLoS One; 2020; 15(2):e0229089. PubMed ID: 32092078
[TBL] [Abstract][Full Text] [Related]
5. VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma.
Liu J; Lin WP; Xiao Y; Yang QC; Bushabu Fidele N; Yu HJ; Sun ZJ
Int Immunopharmacol; 2023 Dec; 125(Pt A):111128. PubMed ID: 37907049
[TBL] [Abstract][Full Text] [Related]
6. Polymorphonuclear myeloid-derived suppressor cells and phosphatidylinositol-3 kinase gamma are critical to tobacco-mimicking oral carcinogenesis in mice.
Nguyen KA; DePledge LN; Bian L; Ke Y; Samedi V; Berning AA; Owens P; Wang XJ; Young CD
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37734878
[TBL] [Abstract][Full Text] [Related]
7. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
[TBL] [Abstract][Full Text] [Related]
8. STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma.
Cui H; Lan Z; Zou KL; Zhao YY; Yu GT
Cancer Immunol Immunother; 2023 May; 72(5):1315-1326. PubMed ID: 36436019
[TBL] [Abstract][Full Text] [Related]
9. Combination of celecoxib and calyculin-A inhibits epithelial-mesenchymal transition in human oral cancer cells.
Velmurugan BK; Hua CH; Tsai MH; Lee CP; Chung CM; Ko YC
Biotech Histochem; 2020 Jul; 95(5):341-348. PubMed ID: 31937145
[TBL] [Abstract][Full Text] [Related]
10. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells in head and neck squamous cell carcinoma.
He JY; Huo FY; Tang HC; Liu B; Bu LL
Int Rev Cell Mol Biol; 2023; 375():33-92. PubMed ID: 36967154
[TBL] [Abstract][Full Text] [Related]
12. β-glucan therapy converts the inhibition of myeloid-derived suppressor cells in oral cancer patients.
Lo YW; Lee AY; Liu YC; Ko HH; Peng HH; Lee HC; Pan PY; Chiang CP; Cheng SJ
Oral Dis; 2022 Sep; 28(6):1484-1495. PubMed ID: 33655573
[TBL] [Abstract][Full Text] [Related]
13. Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck.
Chen WC; Lai CH; Chuang HC; Lin PY; Chen MF
Head Neck; 2017 Feb; 39(2):347-355. PubMed ID: 27696591
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma.
Dar AA; Patil RS; Pradhan TN; Chaukar DA; D'Cruz AK; Chiplunkar SV
Cancer Immunol Immunother; 2020 Jun; 69(6):1071-1086. PubMed ID: 32103293
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic Ras and ΔNp63α cooperate to recruit immunosuppressive polymorphonuclear myeloid-derived suppressor cells in a mouse model of squamous cancer pathogenesis.
Sakakibara N; Clavijo PE; Sievers C; Gray VC; King KE; George AL; Ponnamperuma RM; Walter BA; Chen Z; Van Waes C; Allen CT; Weinberg WC
Front Immunol; 2023; 14():1200970. PubMed ID: 37638000
[TBL] [Abstract][Full Text] [Related]
16. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DNMT1 potentiates antitumor immunity in oral squamous cell carcinoma.
Yang SC; Wang WY; Zhou JJ; Wu L; Zhang MJ; Yang QC; Deng WW; Sun ZJ
Int Immunopharmacol; 2022 Oct; 111():109113. PubMed ID: 35944462
[TBL] [Abstract][Full Text] [Related]
19. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
Maji S; Samal SK; Pattanaik L; Panda S; Quinn BA; Das SK; Sarkar D; Pellecchia M; Fisher PB; Dash R
Oncotarget; 2015 Jun; 6(18):16623-37. PubMed ID: 26009874
[TBL] [Abstract][Full Text] [Related]
20. Metastasized murine oral squamous cell carcinoma cells induce intratumoral polymorphonuclear myeloid derived suppressor cells.
Sumi S; Umemura N; Takayama E; Ohkoshi E; Adachi M; Mizuno-Kamiya M; Inagaki T; Kawaki H; Sumitomo S; Kondoh N
Oncol Rep; 2017 May; 37(5):2897-2904. PubMed ID: 28405677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
